New to Meducation?
Sign up
Already signed up? Log In
view moderators

MedicalOncology

Category

13
2
24

Maintenance Therapy for Advanced NSCLC: When, What, Why, & What’s Left After Post-Maintenance Relapse? (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, summarizes the evidence and presents a current approach to managing treatment of advanced NSCLC after first line therapy.</span></p>  
Howard (Jack) West, MD
about 9 years ago
0
1
12

Maintenance Therapy for Advanced NSCLC: When, What, Why, & What’s Left After Post-Maintenance Relapse? (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, summarizes the evidence and presents a current approach to managing treatment of advanced NSCLC after first line therapy.</span></p>  
Howard (Jack) West, MD
about 9 years ago
1
1
61

Should Surgery be Considered for Very Limited Small Cell Lung Cancer? (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Howard (Jack) West, medical oncologist, President &amp; CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).</span></p>  
Howard (Jack) West, MD
about 9 years ago
2
1
57

Should Surgery be Considered for Very Limited Small Cell Lung Cancer? (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Howard (Jack) West, medical oncologist, President &amp; CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).</span></p>  
Howard (Jack) West, MD
about 9 years ago
3
1
41

Q&A with Dr. Suresh Ramalingam on Individualizing First Line Therapy for Advanced NSCLC (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, discusses questions about individualizing therapy choices for patients with advanced NSCLC.</span></p>  
Howard (Jack) West, MD
about 9 years ago
4
1
40

Q&A with Dr. Suresh Ramalingam on Individualizing First Line Therapy for Advanced NSCLC (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, discusses questions about individualizing therapy choices for patients with advanced NSCLC.</span></p>  
Howard (Jack) West, MD
about 9 years ago
5
1
38

Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.</span></p>  
Howard (Jack) West, MD
about 9 years ago
6
1
59

Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.</span></p>  
Howard (Jack) West, MD
about 9 years ago
7
1
18

The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.</span></p>  
Howard (Jack) West, MD
about 9 years ago
8
1
26

The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.</span></p>  
Howard (Jack) West, MD
about 9 years ago
9
1
53

Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Isolated Brain Metastasis (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of man with an isolated brain metastasis being considered for curative therapy.</span></p>  
Howard (Jack) West, MD
about 9 years ago
10
1
49

Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Isolated Brain Metastasis (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of man with an isolated brain metastasis being considered for curative therapy.</span></p>  
Howard (Jack) West, MD
about 9 years ago
13
1
21

Q&A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Q&amp;A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.</span></p>  
Howard (Jack) West, MD
about 9 years ago
0
1
33

Q&A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Q&amp;A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.</span></p>  
Howard (Jack) West, MD
about 9 years ago
1
1
46

Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Malignant Pleural Mesothelioma (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of a relatively fit man with malignant pleural mesothelioma.</span></p>  
Howard (Jack) West, MD
about 9 years ago
2
1
34

Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Malignant Pleural Mesothelioma (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of a relatively fit man with malignant pleural mesothelioma.</span></p>  
Howard (Jack) West, MD
about 9 years ago
3
2
39

ALK gene rearrangements, ALK inhibitors, and the Lung Cancer Revolution, by Dr. D. Ross Camidge (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. D. Ross Camidge, medical oncologist at the University of Colorado, provides an overview of the newly identified ALK gene rearrangements, novel therapy to target this, and the promise of molecular oncology.</span></p>  
Howard (Jack) West, MD
about 9 years ago
4
1
26

ALK gene rearrangements, ALK inhibitors, and the Lung Cancer Revolution, by Dr. D. Ross Camidge (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. D. Ross Camidge, medical oncologist at the University of Colorado, provides an overview of the newly identified ALK gene rearrangements, novel therapy to target this, and the promise of molecular oncology.</span></p>  
Howard (Jack) West, MD
about 9 years ago
5
1
45

Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Indolent BornchioloAlveolar Carcinoma (BAC) (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion of management options for an elderly man with slowly progressing BAC, with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute.</span></p>  
Howard (Jack) West, MD
about 9 years ago
6
1
63

Expert Round Table with Drs. Anne Tsao and Alex Farivar: Case Discussion on Indolent Bronchioloalveolar Carcinoma (BAC) (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion of management options for an elderly man with slowly progressing BAC, with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute.</span></p>  
Howard (Jack) West, MD
about 9 years ago